RVMD in the 13F filings
Revolution Medicines Inc · CUSIP 76155X100
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 23 Jan 2026
- Managers listing it
- 30
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 7 listed it in both
- Shares listed
- 58,823,923
- combined, among listed positions
- Reported value
- $4.7bn
- combined, at the quarter end
Among the 92 comparable managers: 23 buyers (opened or added shares) and 9 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -1,098,601.
Managers listing RVMD in Q4 2025
30 of 30 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 12,303,502 shares now+947,448
- D. E. Shaw & Co.existing position · 1,613,730 shares now+801,451
- Jane Street Group LLCexisting position · 1,090,416 shares now+492,961
- Point72 Asset Management LPnew position · 446,616 shares now+446,616
- Two Sigma Investments LPexisting position · 421,735 shares now+412,628
Reductions
- Wellington Management Group LLPexisting position · 6,987,639 shares now-2,825,797
- Holocene Advisors LPexisting position · 1,907,948 shares now-1,529,335
- Fidelity (FMR LLC)existing position · 8,587,981 shares now-813,706
- T. Rowe Price Associates Incexisting position · 3,404,717 shares now-468,989
- Woodline Partners LPexisting position · 2,500,895 shares now-414,988
New positions and exits
New (4)
Exited (3)
- Renaissance Technologies LLCwas $12m
- Schonfeld Strategic Advisors LLCwas $1.6m
- ExodusPoint Capital Management LPwas $1.5m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2020 | 4 | $21m | n.a. | n.a. |
| Q2 2020 | 1 | $29m | n.a. | n.a. |
| Q3 2020 | 3 | $388m | n.a. | n.a. |
| Q4 2020 | 4 | $451m | n.a. | n.a. |
| Q1 2021 | 5 | $846m | n.a. | n.a. |
| Q2 2021 | 5 | $325m | n.a. | n.a. |
| Q3 2021 | 3 | $133m | n.a. | n.a. |
| Q4 2021 | 3 | $174m | n.a. | n.a. |
| Q1 2022 | 3 | $174m | n.a. | n.a. |
| Q2 2022 | 3 | $189m | n.a. | n.a. |
| Q3 2022 | 3 | $206m | n.a. | n.a. |
| Q4 2022 | 3 | $263m | n.a. | n.a. |
| Q1 2023 | 5 | $526m | n.a. | n.a. |
| Q2 2023 | 7 | $685m | n.a. | n.a. |
| Q3 2023 | 8 | $766m | n.a. | n.a. |
| Q4 2023 | 8 | $1.0bn | 5 | 3 |
| Q1 2024 | 10 | $1.3bn | 7 | 2 |
| Q2 2024 | 9 | $1.6bn | 4 | 4 |
| Q3 2024 | 10 | $1.9bn | 6 | 3 |
| Q4 2024 | 11 | $2.2bn | 8 | 2 |
| Q1 2025 | 7 | $1.7bn | 5 | 1 |
| Q2 2025 | 8 | $1.7bn | 3 | 4 |
| Q3 2025 | 7 | $2.2bn | 3 | 3 |
| Q4 2025 | 18 | $4.3bn | 23 | 9 |
| Q1 2026 | 15 | $4.8bn | 14 | 20 |
| Q2 2026 | 17 | $10.3bn | 16 | 23 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RVMD and GILD →RVMD and AMGN →RVMD and ARGX →Choose a stock to compare with RVMD →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RVMD, latest filings →Back to the 13F Explorer →